Assessing step-therapy programs:a step in the right direction

J Manag Care Pharm. 2007 Apr;13(3):273-5. doi: 10.18553/jmcp.2007.13.3.273.

Author

Patrick P Gleason¹

Affiliation

¹ Medical and Pharmacy Integration Services, Prime Therapeutics, LLC, Eagan, Minnesota, USA. [email protected]

No abstract available

Publication types

Comment

MeSH terms

Angiotensin II Type 1 Receptor Blockers / economics
Angiotensin-Converting Enzyme Inhibitors / economics
Antihypertensive Agents / economics*
Antihypertensive Agents / therapeutic use
Cost-Benefit Analysis
Drug Costs
Drugs, Generic / economics*
Drugs, Generic / therapeutic use
Eligibility Determination
Humans
Hypertension / drug therapy*
Hypertension / economics*
Insurance Claim Review / economics*
Insurance Claim Review / organization & administration
Insurance, Pharmaceutical Services / economics*
Managed Care Programs / economics*
Managed Care Programs / organization & administration
Outcome Assessment, Health Care
Research Design
Treatment Outcome
United States

Substances

Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Drugs, Generic